Limosilactobacillus reuteri DSM 17648
Limosilactobacillus reuteri DSM 17648 has been studied for adjunctive use in the context of Helicobacter pylori eradication, a bacterial infection associated with gastric ulcers and gastritis. Multiple randomized, double-blind, placebo-controlled trials have examined this strain as a postbiotic (inactivated cell preparation) or as a live culture alongside standard antibiotic eradication therapy, looking at eradication rates and gastrointestinal side effects. A 2026 review has consolidated mechanistic and clinical research on the strain, and it is referenced in a Latin American pediatric gastroenterology position paper on postbiotics. These are research topics, not findings; the papers do not establish that this strain treats or prevents any condition.
Where it's been studied Tags come from a conservative keyword scan of each paper's title, abstract, and summary. A tag is research coverage, not measured effect. How we classify this →
Share of this strain's 9 body-system-tagged papers that concern each system. Research coverage, not measured effect.
Symptoms in the research A tag means the paper's text names the symptom or condition — research coverage, not evidence of benefit. How we classify this →
Share of this strain's 9 symptom-tagged papers that mention each symptom or condition. Research coverage, not evidence of benefit.
Research Study-type filters use AI-classified labels, audited but not guaranteed — check the paper itself before leaning on one. How we classify this →
10 papers reference this strain in the probiotic database.
Discussion
Be the first to comment.
Sign in to join the discussion.
Citations
Selected papers that name this strain.
-
[1]
Source →Strain-specific efficacy of Limosilactobacillus reuteri DSM 17648 in Helicobacter pylori: eradication therapy: A systematic review and meta-analysis· Meditsinskiy sovet = Medical Council · 2026
-
[2]
PMID 39023173 →Efficacy and Safety of Postbiotic Contained Inactivated Lactobacillus reuteri (Limosilactobacillus reuteri) DSM17648 as Adjuvant Therapy in the Eradication of Helicobacter pylori in Adults With Functional Dyspepsia: A Randomized Double-Blind Placebo-Controlled Trial· Clinical and Translational Gastroenterology · 2024
-
[3]
Source →Efficacy and Safety of Postbiotic (Metabiotic) Contained Inactivated Lactobacillus reuteri (Limosilactobacillus Reuteri) DSM 17648 as Adjuvant Therapy in the Eradication of Helicobacter pylori in Adults with Functional Dyspepsia: A Randomized Double-· Preprints.org · 2023
-
[4]
PMID 37614081 →Probiotic containing Lactobacillus reuteri DSM 17648 as an adjunct treatment for Helicobacter pylori infection: A randomized, double‐blind, placebo‐controlled trial· Helicobacter · 2023